MiNK Therapeutics, Inc. Common Stock

INKTNASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
10.66 USD
↘ 0.15 (1.39%)AT CLOSE (11:59 AM EDT)
10.52
↘ 0.14 (1.34%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
10.52
↘ 0.14 (1.34%)
🔴Market: CLOSED

MiNK Therapeutics, Inc. Common Stock (INKT) trades at $10.66 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (98.3%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment.

Technical & fundamental data as of Jul 17, 2026.

Open?$10.76
High?$10.99
Low?$10.43
Prev. Close?$10.81
Volume?25.4K
Avg. Volume?23.3K
VWAP?$10.70
Rel. Volume?1.09x
Bid / Ask
Bid?$10.08 × 100
Ask?$10.95 × 100
Spread?$0.87
Midpoint?$10.52
Valuation & Ratios
Market Cap?53.1M
Shares Out?5.0M
Float?2.0M
Float %?39.2%
P/E Ratio?N/A
P/B Ratio?-4.19
EPS?-$2.50
Dividend?0.00%
Ex-Dividend?N/A
RelatedFTFT
News
Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
15
Market Cap
53.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.minktherapeutics.com
Listed
2021-10-15
Address
149 FIFTH AVENUE
NEW YORK, NY 10010
Phone: 212-994-8250
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
63
Piotroski F-Score?0/9Weak
Altman Z-Score?-23.89Distress
Confidence?46%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?5.76%Elevated
Short Interest?112.5K
Days to Cover?6.1
Free Float2.0M
Avg Daily Volume18.6K
Settlement Date2026-06-30
Financial Health
Current Ratio?1.38Adequate
Quick Ratio?1.38Adequate
Cash Ratio?1.31Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
-4.19CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
97
98.3%STRONG▾
ROA?
S&P
3
-120.2%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$43.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist